Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S.
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback